UGN-101 instillations
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma
Conditions
Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter
Trial Timeline
Oct 1, 2019 → Mar 31, 2020
NCT ID
NCT04006691About UGN-101 instillations
UGN-101 instillations is a phase 3 stage product being developed by UroGen Pharma for Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04006691. Target conditions include Carcinoma, Transitional Cell Carcinoma, Transitional Cell Cancer of the Renal Pelvis and Ureter.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006691 | Phase 3 | Withdrawn |
| NCT02793128 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma